New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

December 2016

Welcome to the December 2016 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the December issue, and happy holidays!

The PharmSource Team


PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type November 2016 YTD 2016
Early Development 110 1296
Late Development 117 1304
Biologic 114 1150
Small Molecule 251 2820
Parenteral 118 1248
Oral 88 1091
New Financings 62 854
Total Drug Leads 338 4101
Total Device &
Diagnostic Leads
132 1544

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

Amryt Pharma plans to initiate a Phase III trial with episalvan for the treatment of epidermolysis bullosa in early 2017:

  • Therapeutic Area: Dermatology
  • Dosage Form: Semi-solid – Sterile
  • API: Botanical

Get deeper information about the likely upcoming needs of Amryt, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

Biosimilars: Like Ryan Reynolds and Ryan Gosling

by Brooke Wilson, Senior Research Analyst

The FDA describes a biosimilar as a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, that has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. Arguably very similar to the two Canadians featured in the title.

As of December 5th, 2016, the EMA had approved 23 biosimilars. The first was in 2006, Omnitrope, produced by Sandoz. In contrast the FDA has only approved… read on

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on Synthetic Biologics, Inc.

Synthetic Biologics, formerly known as Adeona Pharmaceuticals, is a U.S. public bio/pharmaceutical company that develops late-stage, orally available, small molecule drugs for the treatment of neurological and fibrotic diseases. They plan to raise $25 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund the clinical development of its pipeline, including… read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on Genalyte Inc.

Genalyte is a U.S. private company that develops and manufactures next-generation multiplexing instruments and apparatus. They raised $36 million in a completion of a Series D venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the development and regulatory approval of the Maverick Detection System… read on

Bio/Pharma Sponsor Spending on In-house Manufacturing Capacity Soars

This data-rich report, Bio/Pharma CapEx Trends 2016, identifies 3 indicators of what’s ahead for your business:

1. Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

2. Bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years.

3. Based on recent capital expenditure trends, learn why bio/pharma companies would rather “make than buy.”



PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903 (ET USA).